GlaxoSmithKline, Daiichi Sankyo join forces to sell vaccines in Japan

GlaxoSmithKline ($GSK) and Daiichi Sankyo ($D4S.BE) will jointly invest about $1.2 million and pool their vaccine operations into a 50/50 joint venture that they expect will be largest vaccine company in Japan. The Wall Street Journal points out that Japan's market has good growth potential because it currently uses many older vaccines and because the population is only beginning to vaccinate against some conditions that traditionally have been treated symptomatically. The deal is expected to be completed in the third quarter. Release | Story

Suggested Articles

Colorado is making a play for a Japanese CDMO in hopes it will invest about $100 million in an empty AstraZeneca plant in Boulder.

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.